Tag: clinical trials
-
Trial Underway Testing Opioid Dependency Treatments
15 December 2015. A late-stage clinical trial testing weekly and monthly treatments of injected buprenorphine for opioid drug dependence began enrolling patients. The trial is testing the drug code-named CAM2038 developed by the pharmaceutical company Camurus AB in Lund, Sweden, and licensed to Braeburn Pharmaceuticals in Princeton, New Jersey that offers treatments for neurological conditions.…
-
Spin-Off Developing Gene Therapies for Blood Disorders
11 December 2015. A new spin-off company from University College London in the U.K. is developing gene therapies to treat hemophilia and related diseases. The company, Freeline Therapeutics, is raising £25 million ($US 38 million) in its first venture funding round. Freeline Therapeutics is founded and commercializing research by UCL hematology professor Amit Nathwani, who…
-
High Blood Cancer Response Rates Found for Cell Therapies
8 December 2015. Two clinical trials of personalized immune cells to treat blood-related cancers — acute lymphoblastic leukemia in children and non-Hodgkin lymphoma in adults — showed high rates of response and remission. Results of the two trials, conducted by University of Pennsylvania medical school, were reported earlier this week at a meeting of American…
-
Trial Underway Testing Flesh-Eating Bacteria Drug
7 December 2015. A late-stage clinical trial began enrolling patients to test a new treatment for rare, but dangerous bacterial infections that destroy soft tissue and muscle. The trial is testing AB103, a biologic therapy developed by the biotechnology company Atox Bio in Ness Ziona, Israel. AB103 is designed to treat necrotizing soft tissue infections,…
-
Study: Records Database Offers Clinical Trial Savings
3 December 2015. A cost-benefit analysis shows pharmaceutical companies could reap sizable savings in their planning and conduct of clinical trials if they made regular use of a European electronic health records database. The study, led by Data Mining Institute in Geneva, Switzerland with co-authors from several pharmaceutical companies, appears in the January 2016 issue…
-
FDA Approves Antibody Treatment for Lung Cancer
25 November 2015. U.S. Food and Drug Administration yesterday approved necitumumab, an engineered antibody to treat squamous non-small cell lung cancer that spreads to other parts of the body. Necitumumab is marketed under the brand name Portrazza by Eli Lilly and Company. Worldwide, lung cancer causes some 1.6 million deaths, according to World Health Organization. Non-small cell lung…
-
Antibodies to Treat Staph Infections in Early Trial
24 November 2015. A study testing the safety of antibodies to prevent and treat Staphylococcus aureus infections, including those contracted in hospitals, is underway in Vienna, Austria. The clinical trial is evaluating an experimental biologic drug for the prevention and treatment of S. aureus or staph infections made by Arsanis Biosciences, a biotechnology company in…
-
Trial Tests Vibrating Mattress to Prevent Infant Apnea
24 November 2015. A mattress that provides occasional mild vibrations was shown in a clinical trial to prevent episodes of interrupted breathing in preterm babies, a condition known as infant apnea. Results of the study testing the device, developed at the Wyss Institute, a biomedical engineering research center at Harvard University, were reported yesterday in…
-
FDA Approves Nasal Spray for Opioid Overdose
20 November 2015. The U.S. Food and Drug Administration this week approved the first formulation of a current drug to treat opioid overdose in nasal spray form. The Narcan nasal spray is made by Adapt Pharma Ltd., a company headquartered in Dublin, Ireland. Opioids work by reducing the intensity of pain signals to the brain, particularly…
-
Licensing, Research Deal Aims at Chronic Wound Treatments
16 November 2015. Umeå University and the pharmaceutical company Prometic are partnering on development of new treatments for chronic wounds, such as diabetic foot ulcers and bed sores. The agreement gives Prometic, in Laval, Quebec, Canada an exclusive license to the university’s research on the blood plasma protein plasminogen, with the company funding further studies…